PhotoBiotics' CSO presents at World ADC Summit in Frankfurt
London, 01 March 2012:
Dr Mahendra Deonarain, PhotoBiotics' Chief Operating Officer/Chief Scientific
Officer is an invited speaker at Hanson-Wade's 4th World ADC (Antibody Drug Conjugate) Conference
being held in Frankfurt 28th February-1st
March, 20121.
The pioneers of the ADC world will be assembled in Frankfurt to describe recent progress and developments in 'harnessing the promise of empowered antibodies'. Dr Deonarain will be closing the meeting, focusing on the multiple opportunities offered by PhotoBiotics' OptiLink platform in combination with its proprietary light-activatable drugs. Uniquely, PhotoBiotics' ADCs are based on antibody fragments, which offer considerable advantages over whole antibody-based ADCs, particularly regarding therapeutic window and the ability to penetrate solid tumours much more efficiently.
ADC targeted therapy is one of the most rapidly expanding areas in the biotech sector, with significant partnership deals being sealed and major innovation happening. The first of the new generation ADCs has just been approved for Hodgkin's lymphoma, and others are in the pipeline2. Major pharmaceutical companies are taking a real interest, leading to licensing opportunities for biotechnology companies specialising in antibody-drug conjugation technologies.
However, Dr Deonarain comments "Although very promising, conventional ADCs still have limitations which can be largely overcome using PhotoBiotics' OptiLink technology combined with light-activatable drugs".
Notes for Editors:
1. http://adcsummit-europe.com/
2. Pharma interest surges in antibody drug conjugates, SarahWebb, Nature Biotechnology, April 2011. http://www.nature.com/nbt/journal/v29/n4/full/nbt0411-297.html
About PhotoBiotics
PhotoBiotics Ltd is a multidisciplinary company spun out from Imperial College London to explore ways of targeting drugs directly to tumours, thus enhancing the efficacy of cancer treatment while also reducing unwelcome side-effects. The Company has developed a unique and simple antibody-drug conjugate (ADC) technology platform, denoted OptiLink™, which enables the multiple attachment of drugs to antibody fragments. Counter-intuitively, OptiLink™ allows far higher drug loadings on antibody fragments than normally achieved with whole monoclonal antibodies. The PhotoBiotics' R&D team has already succeeded in its initial objective of targeting photosensitiser-based drugs to tumours, generating compelling efficacy data in various orthotopic and xenograft models, and has a product ready to enter preclinical toxicology / clinical development. The Company is now exemplifying how OptiLink™ has utility across a wide range of other ADC applications, including the targeted delivery of conventional cytotoxic drugs and MRI (Magnetic Resonance Imaging) contrast agents.
Press Releases
- PhotoBiotics' CSO presents at Innovate UK 2013
Date : 11 March 2013
- PhotoBiotics' awarded a TSB Biomedical Catalyst Feasibility Award
Date : 1 November 2012 - PhotoBiotics' CSO presents at the Application of Monoclonal Antibodies in Clinical Oncology Conference
Date : 25 June 2012 - PhotoBiotics' CSO presents at the Empowered Antibodies Congress
Date : 12 June 2012 - PhotoBiotics' CSO presents at the Inaugural SMi ADC Summit
Date : 24 May 2012 - PhotoBiotics' CSO presents at World ADC Summit in Frankfurt
Date : 01 March 2012 - PhotoBiotics' COO presents at major Antibody Drug Conjugate (ADC) conference in Barcelona
Date : 09 November 2011 - PhotoBiotics presents OptiLinkTM Antibody-drug conjugate (ADC) platform at World ADC Summit in San Francisco
Date : 25 October 2011 - PhotoBiotics Raises Further Funding for Antibody Drug Conjugates (ADCs)
Date : 11 October 2011 - PhotoBiotics' CSO hosts Antibody Drug Conjugate (ADC) event at Berlin Novel Protein Therapeutics Conference
Date : 27 September 2011 - A Conjugation Platform for the Targeted Delivery of Anticancer Agents
Date : 01 September 2011 - OptiLink ADC Technology Features at the 10th Annual Congress on Recombinant Antibodies
Date : 15 May 2011 - PhotoBiotics Announces Collaboration with Major Pharma Company
Date : 7 December 2010 - PhotoBiotics’ approach to Targeted Magnetic Resonance Imaging receives award from the National Institute for Health Research
Date : 6 September 2010 - Location! Location! Location! - PhotoBiotics' Key to Successful PDT
Date : 31 July 2010 - US patent granted to PhotoBiotics for new targeted cancer therapy
Date : 1 April 2010 - Targeted Photodynamic Therapy in Corfu and Wroclaw 2009
Date : 22 June 2009 - American Chemical Society Hosts Targeted Photodynamic Therapy at Salt Lake City
Date : 10 April 2009 - Patent for targeted photodynamic therapy (t-PDT) gets green light Down Under
Date : 7 October 2008 - Targeted Photodynamic Therapy (t-PDT) to light up Brixen / Bressanone Symposium
Date : 18 September 2008 - Novel Targeted Cancer Therapy on show at Dubrovnik
Date : 24 March 2008 - New targeted anti-cancer therapy lights up investors
Date : 29 January 2008 - Light-activated anti-cancer drugs on target
Date : 29 November 2007